Boehringer Ingelheim to Present New Research on Pradaxa and Specific Reversal Agent Praxbind at American College of Cardiology Scientific Session
Boehringer Ingelheim to Present New Research on Pradaxa and Specific Reversal Agent Praxbind at American College of Cardiology Scientific Session
- Data includes sub-analyses from RE-VERSE AD(TM) and RE-DUAL PCI(TM) trials, published in the New England Journal of Medicine in 2017, and the RE-COVERY DVT/PE(TM) trial
RIDGEFIELD, Conn., March 9, 2018 /PRNewswire/ -- Boehringer Ingelheim today announced that important sub-analyses from three major trials will be presented at the American College of Cardiology (ACC) 67(th) Annual Scientific Session, to be held March 10-12 in Orlando, Florida. In total, six abstracts have been accepted examining the novel oral anticoagulant, Pradaxa® (dabigatran etexilate mesylate), and its specific reversal agent, Praxbind® (idarucizumab). The sub-analyses provide further data on the use of Pradaxa and Praxbind in a diverse group of patients, including non-valvular atrial fibrillation (NVAF) patients who have undergone percutaneous coronary intervention with stenting, patients with uncontrollable bleeding or needing an emergency procedure, and patients with acute deep vein thrombosis or pulmonary embolism.
"Boehringer Ingelheim is proud to continue its research in anticoagulation care to help better meet the diverse and evolving needs of both patients and healthcare providers," said Thomas Seck, M.D., vice president, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "The safety and efficacy of Pradaxa and Praxbind are well-established and we look forward to sharing results from these new analyses, which we believe will provide further insight on the role these treatments can play for a range of patients."
Details of the data to be presented at the ACC 67(th) Annual Scientific Session are as follows:
Abstract Title Details
(Venue: Orange County Convention Center, Orlando Florida)
--- --------------------------------------------------------
Does Renal Function Influence
the Benefit of Dual
Antithrombotic Therapy With
Dabigatran in Patients with
Atrial Fibrillation
Undergoing Percutaneous
Coronary Intervention?
Results from RE-DUAL PCI Session Title: 1101 - Anticoagulation For the Appropriate
Patient in Atrial Fibrillation
Session Date: Saturday, March 10, 9:30 a.m. - 12:30 p.m.
Presentation Time: 10:00 a.m. - 10:45 a.m.
Location: Poster Hall, Hall A/B
Speaker: Stefan Hohnloser
--- -------------------------
Bleeding Events and Their
Consequences on
Cardiovascular Events,
Readmission and Net Clinical
Benefit Session Title: 1155 - Outcomes After Myocardial
Infarction and Percutaneous Coronary Intervention
Session Date: Saturday, March 10, 1:30 p.m. - 4:30 p.m.
Presentation Time: 3:45 p.m. - 4:30 p.m.
Location: Poster Hall, Hall A/B
Speaker: Philippe Steg
--- ----------------------
Relation of Stroke and
Bleeding Risk Profiles to
Efficacy and Safety of
Dabigatran in Atrial
Fibrillation After PCI: An
Ancillary Analysis from the
RE-DUAL PCI Trial Session Title: 1216M - Arrhythmias and Clinical EP: New
Drugs, New Insights
Session Date: Sunday, March 11, 9:45 a.m. - 10:30 a.m.
Presentation Time: 9:45 a.m. - 9:55 a.m.
Location: Arrhythmias and Clinical EP Moderated Poster Theater, Poster Hall, Hall A/B
Speaker: Gregory Lip
--- --------------------
Is It Safe to Switch OAC in
Patients With Atrial
Fibrillation Undergoing
Percutaneous Coronary
Intervention? Results From a
RE-DUAL PCI Subanalysis Session Title: 1194 - Switching Antithrombotic Therapies
and Genetic and Platelet Function Testing
Session Date: Sunday, March 11, 9:30 a.m. - 12:30 p.m.
Presentation Time: 9:45 a.m. - 10:30 a.m.
Location: Poster Hall, Hall A/B
Speaker: Jurrien Ten Berg
--- -------------------------
Renal Impairment Does Not
Compromise Dabigatran
Reversal by Idarucizumab Session Title: 1231M - The Clot Thickens: Advances in
Venous Thromboembolism and Anticoagulation
Session Date: Sunday, March 11, 12:30 p.m. - 1:45 p.m.
Presentation Time: 1:30 p.m. - 1:40 p.m.
Location: Vascular Medicine and Valvular Heart Disease
Moderated Poster Theater, Poster Hall, Hall A/B
Speaker: John W. Eikelboom
--- --------------------------
Characterization of 6,122
Patients With Acute Venous
Thromboembolism in Routine
Clinical Practice: RE-COVERY
DVT/PETM Prospective Global
Cohort Study Session Title: 1300 - We're So Vein! Emerging Concepts
in the Diagnosis and Treatment of Venous Thromboembolism
Session Date: Monday, March 12, 9:30 a.m. - 12:30 p.m.
Presentation Time: 9:45 a.m. - 10:30 a.m.
Location: Poster Hall, Hall A/B
Speaker: Ivan Casella
--- ---------------------
More information on the Boehringer Ingelheim data due to be presented or published at the ACC 67(th) Annual Scientific Session and Expo can be found here.
Praxbind is the first and only approved specific reversal agent for a novel oral anticoagulant currently available. It is approved as a specific reversal agent for Pradaxa by the U.S. Food and Drug Administration (FDA) under accelerated approval. Continued approval for this indication may be contingent upon the results of an ongoing cohort case series study.
About Praxbind® (idarucizumab)
INDICATIONS AND USAGE
PRAXBIND is indicated in patients treated with Pradaxa® when reversal of the anticoagulant effects of dabigatran is needed:
-- For emergency surgery/urgent procedures
-- In life?threatening or uncontrolled bleeding
This indication is approved under accelerated approval based on a reduction in unbound dabigatran and normalization of coagulation parameters in healthy volunteers. Continued approval for this indication may be contingent upon the results of an ongoing cohort case series study.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Thromboembolic Risk
-- Dabigatran-treated patients have underlying diseases predisposing them
to thromboembolic events. Reversing dabigatran therapy exposes patients
to the thrombotic risk of their underlying disease. To reduce this
risk, resumption of anticoagulant therapy should be considered as soon
as medically appropriate.
Re-elevation of Coagulation Parameters
-- Elevated coagulation parameters (e.g., activated partial thromboplastin
time or ecarin clotting time) have been observed in a limited number of
PRAXBIND-treated patients. If reappearance of clinically relevant
bleeding together with elevated coagulation parameters is observed or if
patients requiring a second emergency surgery/urgent procedure have
elevated coagulation parameters, an additional full dose may be
considered.
Hypersensitivity Reactions
-- There is insufficient clinical experience evaluating risk of
hypersensitivity to idarucizumab, but a possible relationship could not
be excluded. Risk of hypersensitivity (e.g., anaphylactoid reaction) to
idarucizumab or excipients needs to be weighed cautiously against the
potential benefit. If serious allergic reaction occurs, immediately
discontinue PRAXBIND and institute appropriate treatment.
Risk in Patients with Hereditary Fructose Intolerance
-- PRAXBIND contains 4 g sorbitol as an excipient. When prescribing
PRAXBIND in patients with hereditary fructose intolerance consider the
total daily amount of sorbitol/fructose consumption from all sources as
serious adverse reactions (e.g. hypoglycemia, hypophosphatemia,
metabolic acidosis, increase in uric acid, acute liver failure and
death) may occur.
ADVERSE REACTIONS
-- The most frequently reported adverse reaction in >=5% of
idarucizumab-treated healthy volunteers was headache (12/224). The most
frequently reported adverse reactions in >=5% of patients were
hypokalemia (9/123), delirium (9/123), constipation (8/123), pyrexia
(7/123) and pneumonia (7/123).
-- As with all proteins there is a potential for immunogenicity with
idarucizumab. In treated patients, treatment-emergent antibodies with
low titers were observed (9/224).
USE IN SPECIFIC POPULATIONS
Pregnancy and Nursing Mothers
-- PRAXBIND should be given to a pregnant or nursing woman only if clearly
needed.
Please see full Prescribing Information.
About Pradaxa® (dabigatran etexilate mesylate)
Indications and Usage
Pradaxa® (dabigatran etexilate mesylate) capsules is indicated:
-- to reduce the risk of stroke and systemic embolism in patients with
non-valvular atrial fibrillation
IMPORTANT SAFETY INFORMATION ABOUT PRADAXA
WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA
(A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTS
Premature discontinuation of any oral anticoagulant, including Pradaxa, increases the risk of thrombotic events. If anticoagulation with Pradaxa is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant
(B) SPINAL/EPIDURAL HEMATOMA
Epidural or spinal hematomas may occur in patients treated with Pradaxa who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:
-- use of indwelling epidural catheters
-- concomitant use of other drugs that affect hemostasis, such as
non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors,
other anticoagulants
-- a history of traumatic or repeated epidural or spinal punctures
-- a history of spinal deformity or spinal surgery
-- optimal timing between the administration of Pradaxa and neuraxial
procedures is not known
Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary. Consider the benefits and risks before neuraxial intervention in patients who are or will be anticoagulated.
CONTRAINDICATIONS
Pradaxa is contraindicated in patients with:
- active pathological bleeding;
- known serious hypersensitivity reaction (e.g., anaphylactic reaction or anaphylactic shock) to Pradaxa;
- mechanical prosthetic heart valve
WARNINGS & PRECAUTIONS
Increased Risk of Thrombotic Events after Premature Discontinuation
Premature discontinuation of any oral anticoagulant, including Pradaxa, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. If Pradaxa is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant and restart Pradaxa as soon as medically appropriate.
Risk of Bleeding
-- Pradaxa increases the risk of bleeding and can cause significant and,
sometimes, fatal bleeding. Promptly evaluate any signs or symptoms of
blood loss (e.g., a drop in hemoglobin and/or hematocrit or
hypotension). Discontinue Pradaxa in patients with active pathological
bleeding.
-- Risk factors for bleeding include concomitant use of medications that
increase the risk of bleeding (e.g., anti-platelet agents, heparin,
fibrinolytic therapy, and chronic use of NSAIDs). Pradaxa's
anticoagulant activity and half-life are increased in patients with
renal impairment.
-- Reversal of Anticoagulant Effect: A specific reversal agent
(idarucizumab) for dabigatran is available when reversal of the
anticoagulant effect of dabigatran is needed:
-- For emergency surgery/urgent procedures
-- In life-threatening or uncontrolled bleeding
Hemodialysis can remove dabigatran; however clinical experience for hemodialysis as a treatment for bleeding is limited. Prothrombin complex concentrates or recombinant Factor VIIa may be considered but their use has not been evaluated. Protamine sulfate and vitamin K are not expected to affect dabigatran anticoagulant activity. Consider administration of platelet concentrates where thrombocytopenia is present or long-acting antiplatelet drugs have been used.
Thromboembolic and Bleeding Events in Patients with Prosthetic Heart Valves
The use of Pradaxa is contraindicated in patients with mechanical prosthetic valves due to a higher risk for thromboembolic events, especially in the post-operative period, and an excess of major bleeding for Pradaxa vs. warfarin. Use of Pradaxa for the prophylaxis of thromboembolic events in patients with AFib in the setting of other forms of valvular heart disease, including bioprosthetic heart valve, has not been studied and is not recommended.
Effect of P-gp Inducers & Inhibitors on Dabigatran Exposure
Concomitant use of Pradaxa with P-gp inducers (e.g., rifampin) reduces exposure to dabigatran and should generally be avoided. P-gp inhibition and impaired renal function are major independent factors in increased exposure to dabigatran. Concomitant use of P-gp inhibitors in patients with renal impairment is expected to increase exposure of dabigatran compared to either factor alone.
Reduction of Risk of Stroke/Systemic Embolism in NVAF
-- For patients with moderate renal impairment (CrCl 30-50 mL/min), reduce
the dose of Pradaxa to 75 mg twice daily when dronedarone or systemic
ketoconazole is coadministered with Pradaxa.
-- For patients with severe renal impairment (CrCl 15-30 mL/min), avoid
concomitant use of Pradaxa and P-gp inhibitors.
ADVERSE REACTIONS
The most serious adverse reactions reported with Pradaxa were related to bleeding.
-- Most frequent adverse reactions leading to discontinuation of Pradaxa
were bleeding & gastrointestinal (GI) events.
-- Pradaxa 150 mg resulted in higher rates of major and any GI bleeds
compared to warfarin.
-- In patients >=75 years of age, the risk of major bleeding may be greater
with Pradaxa vs warfarin.
-- Patients on Pradaxa 150 mg had an increased incidence of GI adverse
reactions. These were commonly dyspepsia (including abdominal pain
upper, abdominal pain, abdominal discomfort, and epigastric discomfort)
and gastritis-like symptoms (including GERD, esophagitis, erosive
gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic
erosive gastritis, and GI ulcer)
Other Measures Evaluated
In NVAF patients, a higher rate of clinical MI was reported in patients who received Pradaxa (0.7/100 patient-years for 150 mg dose) than in those who received warfarin (0.6).
Please see full Prescribing Information, including boxed WARNING and Medication Guide.
About Boehringer Ingelheim
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation.
Boehringer Ingelheim is one of the world's top 20 pharmaceutical companies. Headquartered in Ingelheim, Germany, the company operates globally with approximately 50,000 employees. Since its founding in 1885, the company has remained family-owned and today creates value through innovation for three business areas including human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.
Boehringer Ingelheim is committed to improving lives and providing valuable services and support to patients and their families. Our employees create and engage in programs that strengthen our communities. Please visit our website to learn more about how we make more health for more people through our Corporate Social Responsibility initiatives.
In 2016, Boehringer Ingelheim achieved net sales of about $17.6 billion (15.9 billion euros). R&D expenditure corresponds to 19.6 percent of its net sales.
For more information please visit www.boehringer-ingelheim.us, or follow us on Twitter @BoehringerUS.
Boehringer Ingelheim Pharmaceuticals, Inc. either owns or uses the trademarks Pradaxa®, Praxbind®, RE-VERSE AD(TM), RE-DUAL PCI(TM) and RE-COVERY DVT/PE(TM) under license.
CONTACT: Boehringer Ingelheim Pharmaceuticals, Inc., Lauren Murphy, Public Relations, Phone: 203-448-1982, Email: lauren.murphy@boehringer-ingelheim.com
SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
